2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P2831
    Esterase, pig liver 9016-18-6
    Esterase, pig liver (CESs), namely carboxylate hydrolases, are widely distributed in nature, commonly found in mammalian liver, and often used in biochemical research. Esterase catalyzes the hydrolysis of a variety of endogenous and exogenous substrates, including esters, thioesters, carbamates, and amides, hydrolyzing carboxylic acid esters to the corresponding alcohols and carboxylic acids.
    Esterase, pig liver
  • HY-P4157
    FOXO4-DRI 2460055-10-9 99.93%
    FOXO4-DRI is a cell-permeable peptide antagonist that blocks the interaction of FOXO4 and p53. FOXO4-DRI is a senolytic peptide that induces apoptosis of senescent cells.
    FOXO4-DRI
  • HY-Y1644
    (E)-Crotonic acid 107-93-7 ≥98.0%
    NSC 8751 (trans-2-Butenoic acid; trans-Crotonic acid) is an unsaturated carboxylic acid compound containing α,β-unsaturated carboxylic acid groups. NSC 8751 is one of the important analogs for evaluating the safety of fragrance ingredients and is used to evaluate the toxicological properties of compounds with similar structures. When NSC 8751 is applied to local lymph nodes, a 50% concentration does not cause skin sensitization. Structural analogs of NSC 8751 have been shown to be non-genotoxic. trans-Crotonic acid can be used in the preparation of cosmetics and food additives.
    (E)-Crotonic acid
  • HY-101017
    Palmitoylcarnitine chloride 6865-14-1 ≥98.0%
    Palmitoylcarnitine chloride is a fatty acid-derived mitochondrial substrate, and selectively decreases cell survival in colorectal and prostate cancer cells by affecting on pro-inflammatory pathways, Ca2+ influx, and DHT-like effects.
    Palmitoylcarnitine chloride
  • HY-107399
    CD3254 196961-43-0 98.18%
    CD3254 a potent and selective retinoid-X-receptor (RXR) agonist.
    CD3254
  • HY-112945
    MLS0315771 727664-91-7 99.46%
    MLS0315771 is a potent and biologically active competitive phosphomannose isomerase (MPI) inhibitor, with an IC50 ~1 μM and a Ki of 1.4 μM.
    MLS0315771
  • HY-113261
    Oleoylcarnitine 38677-66-6 ≥98.0%
    Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via STAT3 activation.
    Oleoylcarnitine
  • HY-117755
    PF-739 1852452-14-2 99.79%
    PF-739 is an orally active and non-selective activator of AMPK. PF-739 activates 12 heterotrimeric AMPK complexes and significantly reduces the level of glucose in plasma complexes.
    PF-739
  • HY-148104
    ACSS2-IN-2 2332820-04-7 99.49%
    ACSS2-IN-2 is an acyl-CoA synthetase short-chain family member 2 (ACSS2) inhibitor. ACSS2-IN-2 can inhibit ACSS2 activity with an IC50 value of 3.8 nM. ACSS2-IN-2 can be used for the research of several diseases, such as viral infection, metabolic disorders, neuropsychiatric diseases, inflammatory/autoimmune conditions and cancer.
    ACSS2-IN-2
  • HY-N0324A
    Cholic acid sodium 361-09-1 ≥98.0%
    Cholic acid sodium is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid sodium is orally active.
    Cholic acid sodium
  • HY-P0055A
    GLP-1(7-37) acetate 1450806-98-0 99.63%
    GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
    GLP-1(7-37) acetate
  • HY-111355B
    Cholesteryl sulfate sodium 2864-50-8 ≥98.0%
    Cholesteryl sulfate sodium is an orally available, NPC2-targeted cholesterol biosynthesis agonist. Cholesteryl sulfate sodium activates SREBP2 by competitively binding to NPC2, promoting cholesterol synthesis (EC50=50 μM). Cholesteryl sulfate sodium enhances the self-assembly ability of Mitoxantrone hydrochloride (HY-13502A), while repairing the intestinal mucosal barrier and inhibiting inflammation by regulating serine protease activity and PKCη signaling pathway. Cholesteryl sulfate sodium is a component of the platelet cell membrane and supports platelet adhesion. Cholesteryl sulfate sodium also regulates the activity of selective protein kinase C isoforms and modulates the specificity of PI3K, playing a role in keratinocyte differentiation.
    Cholesteryl sulfate sodium
  • HY-B2132
    Tryptamine 61-54-1 99.77%
    Tryptamine is a selective, blood-brain-penetrating 5-HT4 receptor agonist (EC50=1-3 mM) and an endogenous ligand of the aryl hydrocarbon receptor (AHR) (Kd=10-50 nM). Tryptamine promotes intestinal anion secretion and fluid transport by activating G protein-coupled receptors (GPCRs) and accelerates gastrointestinal motility. Tryptamine regulates Th17/Treg balance to inhibit neuroinflammation, competitively binds to 5-HT receptors to regulate central nervous system activity, and participates in temperature regulation and spinal reflex regulation as a neuromodulator. Tryptamine can be used to study intestinal motility disorders such as functional constipation, and has shown significant efficacy in multiple sclerosis models.
    Tryptamine
  • HY-103007
    TC-G-1008 1621175-65-2 99.36%
    TC-G-1008 (GPR39-C3) is a potent and orally available GPR39 agonist with EC50 values of 0.4 and 0.8 nM for rat and human receptors respectively.
    TC-G-1008
  • HY-N9410
    Lysophosphatidylcholine 18:2 22252-07-9
    Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment.
    Lysophosphatidylcholine 18:2
  • HY-100953
    CYM-5520 1449747-00-5 99.48%
    CYM-5520 is a selective and allosteric sphingosine 1-phosphate receptor 2 (S1PR2) agonist with an EC50 of 480 nM. CYM-5520 does not activate S1PR1, S1PR3, S1PR4 and S1PR5 receptors. CYM-5520 can co-bind in the S1PR2 receptor with S1P. CYM-5520 can be used for osteoporosis research.
    CYM-5520
  • HY-103334
    MAFP 188404-10-6 ≥98.0%
    MAFP (Methyl Arachidonyl Fluorophosphonate) is an selective, active-site directed and irreversible inhibitor of cPLA2 and iPLA2. MAFP is also a potent irreversible inhibitor of anandamide amidase.
    MAFP
  • HY-107928
    Iron dextran 9004-66-4
    Iron dextran (Fe dextran) can be used in the study of iron-deficiency anemia in animals.
    Iron dextran
  • HY-114365
    UDP-GalNAc disodium 108320-87-2 99.98%
    UDP-GalNAc (UDP-N-acetyl-D-galactosamine) disodium is a sugar nucleotide and a substrate of EpsC115. EpsC115 is an exopolymeric substances (EPS) N-terminal deletion mutant with the residue 1-115 deletion. UDP-GalNAc UDP-GalNAc is the donor substrate of many N-acetylgalactosaminyltransferases, enzymes which transfer GalNAc from the nucleotide sugar to a saccharide or peptide acceptor.
    UDP-GalNAc disodium
  • HY-139290
    RGLS4326 2229964-07-0 99.06%
    RGLS4326 (RG4326) is a first-in-class, short oligonucleotide inhibitor of microRNA-17 (miR-17). RGLS4326 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 inhibits miR-17 function in HeLa cells with an EC50 value of 28.3 nM.
    RGLS4326
Cat. No. Product Name / Synonyms Application Reactivity